????????/???????_???????|???????????????

??????????1.3-1.7???????????????????HCV?????????????????????????????????????????????????????????????????????????HCV???????????????????????????????????????????????????????????????Τ???PEG/RBV??????????????1???4???????У?PEG/RBV??????????????????50%?????????????????????????????80%??

2013???????Τ??Sovaldi????2014???????Harvoni????????????????????????????????DAA??????????HCV??????￡???????????С??????????PEG/RBV?????????SVR??????100%????????????????????????????????????????????????е???????????FDA???????????????μ????Ч??DAA????????????????????????????????????????????????????????????У?????о???2???3?????顣??Щ???????????????е??????????????????????????????????????????????÷??棬?????????????????????????????????????е?????????

???????й?????λ?????????1000-3000???????DAA????????????Τ??????Τ???????????й????У?????????????????500λ????????????????????Щ??Ч?????????Ч????????????????????????Щ??????????????????????????????й???????DAA????????????о???????????????????????????о??????clinicaltrials.gov??????????????????????????????????????????й????????DAA????????Ч????????????????????????????о????????????????л?????????????????????????????????????μ???????????????о?????????й????λ???????????????????????????

??????е????

1. ???????л????????о?????

2. ????????????????????

??????綽??17199912074????zhulan@kangantu.com

?????馽?????????????????????????й????????????????о?????й????????????????о???????????????????????????????????????????Ч??????????????????????????????????????????????????е??????????????????????????????????λ???????????????????????????????????????????????????????????????????????????????????????????????????????????

?????????????????????????????塱???????塱???????????????????????????ο????????????????????????????о?(clinnicaltrials.gov ????: NCT01434212 and NCT01760148)?????з???????о????飬????????е??????

?????????????????????????????????????????????????????о????????Ч????????о????? ????п?????????????????????????????????????????ο??????????????? ?й??????????????о???

??????????????

1Hu Y, Mao K, Zeng Y, Chen S, Tao Z, Yang C, Sun S, et al. Tripartite-motif protein 30 negatively regulates NLRP3 inflammasome activation by modulating reactive oxygen species production. J Immunol 2010;185:7699-7705.
2Wang Y, Yang C, Mao K, Chen S, Meng G, Sun B. Cellular localization of NLRP3 inflammasome. Protein Cell 2013;4:425-431.
3Shi X, Chi X, Pan Y, Gao Y, Li W, Yang C, Zhong J, et al. IL28B is associated with outcomes of chronic HBV infection. Yonsei Med J 2015;56:625-633.
4Yang C, Zhao X, Sun D, Yang L, Chong C, Pan Y, Chi X, et al. Interferon alpha (IFNalpha)-induced TRIM22 interrupts HCV replication by ubiquitinating NS5A. Cell Mol Immunol 2016;13:94-102.
5Dachuan Li, Qing Li, Nong Cheng, Jingyan Song. ??Sampling-based real-time motion planning under state uncertainty for autonomous micro aerial vehicles in GPS-denied environments??. Sensors, 2014, 14(11): pp21791-218256.
6Dachuan Li, Qing Li, Liangwen Tang, Sheng Yang, Nong Cheng, Jingyan Song. "Invariant Observer-Based State Estimation for Micro-Aerial Vehicles in GPS-Denied Indoor Environments Using an RGB-D Camera and MEMS Inertial Sensors". Micromachines, 2015, 6(4): pp 487-522
7Qing Li, Dachuan Li, Qinfan Wu, Liangwen Tang, Yan Huo, Yixuan Zhang, Nong Cheng. ??Autonomous navigation and environment modeling for MAVs in 3-D enclosed industrial environments,?? Computer in Industry, vol.64, no.9: pp 1161-1177, 2013
8Dachuan Li, Qing Li, Nong Cheng, Jingyan Song, ??Extended RRT-based path planning for flying robots in complex 3D environments with narrow passages,?? in IEEE International Conference on Automation Science and Engineering (CASE), 2012.
9Dachuan Li, Qing Li, Nong Cheng, Qinfan Wu, Jingyan Song, Liangwen Tang, ??Combined RGBD-inertial based state estimation for MAV in GPS-denied indoor environments,?? in 9th Asian Control Conference, 2013.
10Dachuan Li, Qing Li, Nong Cheng, Qinfan Wu, Jingyan Song, Liangwen Tang, ??Invariant observer design of a RGB-D aided inertial system for micro aerial vehicles in GPS-denied environments??, in IEEE International Conference on Systems, Man and Cybernetics (SMC), 2013.

?????????????????

Abstract: About 130-170 million people, is estimated to be infected with the hepatitis C virus (HCV). Chronic HCV infection is one of the leading causes of liver- related death and in many countries it is the primaryreason for having a liver transplant. The main aim of antiviral treatment is to eradicate the virus. Until a few years ago the only treatment strategy was based on the combination of pegylated interferon and ribavirin (PEG/RBV). However, in genotypes 1 and 4 the rates of viral response did not surpass 50%, reaching up to 80% in the rest. In 2013 and 2014 approval were given for the direct acting antiviral agents (DAA), sovaldi and harvoni, serially, for treatment of HCV patients. These DAA created a new scenario: shorter therapies, less toxicity (free of PEG/RBV), increased rates of SVR (even up to 100%), with pan-genomic properties and excellent tolerance.This has enabled their almost generalised applicability in all patients. Recent years, FDA approved a series of new more effective DAA, However, it should be noted that most of the scientific evidence available is based on expert opinion, case-control series, cohort studies and phase 2 and 3 trials, some with a reduced number of patients and select groups. Few data are currently available about the use of these drugs in daily clinical practice, particularly in relation to the appearance of side effects and interactions with other drugs, or their use in special populations or persons with the less common genotypes. This situation suggests the need for the generalised implementation of registries of patients receiving antiviral therapy. In a clinical study carried out in china, 500 HCV patients received recent DAA treatment. The results indicate that...

Key words: Hepatitis C; Treatment; Direct acting antiviral agents; Chinese Patients; Outcome

??????綽??17199912074????zhulan@kangantu.com